Skip to content
Peptide research

TRH

Also known as Thyrotropin-Releasing Hormone · Protirelin
Category
Brain & Cognition
Administration routes
InjectableNasal
Regulatory status
Not FDA-approved

A tripeptide that triggers pituitary release of TSH and prolactin, used off-label for effects on mood, alertness, and seizure threshold. Anticonvulsant and arousal-reversing effects have modest evidence, but neuroprotection claims rest almost entirely on animal studies. The main risk is thyroid axis disruption and blood pressure shifts, worsened by a short half-life. It is not an FDA-approved drug and is sourced as unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Thyrotropin-Releasing Hormone (TRH) is a tripeptide (pyroGlu-His-Pro-NH2) originally discovered as the hypothalamic neurohormone responsible for stimulating thyroid-stimulating hormone (TSH) release from the anterior pituitary. Its discovery by Andrew Schally and Roger Guillemin earned them the 1977 Nobel Prize in Physiology or Medicine. However, research has revealed that TRH has remarkable neuromodulatory and neuroprotective properties that are entirely independent of its thyroid axis effects.

Beyond its classical endocrine role, TRH is widely distributed throughout the brain and spinal cord where it functions as a neurotransmitter and neuromodulator. TRH has potent analeptic (arousal-promoting) effects, acts as an endogenous anticonvulsant, protects neurons against excitotoxic damage from glutamate, and stabilizes mood and cognition. These CNS effects are mediated by TRH receptor 1 (TRH-R1) and TRH receptor 2 (TRH-R2) and involve modulation of glutamate, GABA, acetylcholine, and monoamine neurotransmission. TRH also protects against hippocampal cell death induced by excitatory amino acids.

TRH has shown therapeutic promise in clinical settings including traumatic brain injury, spinal cord injury, epilepsy, depression, and neurodegenerative diseases. Protirelin (synthetic TRH) is approved in some countries for diagnostic use and was previously used therapeutically. TRH analogs such as taltirelin (approved in Japan for spinocerebellar degeneration) extend the half-life and neuroprotective effects of the native peptide, confirming the translational potential of targeting the TRH system.

How it works in the body

Thyrotropin-Releasing Hormone is a tripeptide (pGlu-His-Pro) that activates TRH receptors in the pituitary to release TSH and prolactin. Beyond thyroid regulation, it has independent neuromodulatory effects — it acts as an endogenous anticonvulsant, counters respiratory depression, has antidepressant properties, and provides neuroprotection against excitotoxicity.

Research overview

TRH has been studied for over five decades with a dual identity: a classical hypothalamic releasing hormone and a broadly acting neuroprotective agent. Over 12,000 PubMed publications cover TRH, though the majority focus on its endocrine functions. The neuroprotective research is substantial. TRH reduced NMDA-induced excitotoxic damage in acutely dissected rat hippocampal slices (Pizzi et al., Eur J Pharmacol 1999). In traumatic brain injury models, TRH and its analogs improve neurological outcomes, reduce edema, and enhance recovery (Faden, CNS Drug Reviews 2002). A review (Alvarez-Salas et al., Int J Mol Sci 2023) summarized renewed efforts to develop TRH as a therapeutic agent, noting its anti-inflammatory, anti-apoptotic, and neurotrophic properties. The TRH analog taltirelin protects dopaminergic neurons from MPTP and rotenone toxicity in Parkinson's disease models by reducing ROS generation, lowering phosphorylated tau and alpha-synuclein, and inhibiting MAO-B activity (Zheng et al., Front Cell Neurosci 2018). TRH has also been studied in depression (it has intrinsic antidepressant-like effects), epilepsy (it is an endogenous anticonvulsant), and amyotrophic lateral sclerosis. The major limitation of TRH is its extremely short plasma half-life (~5 minutes), which has driven development of stabilized analogs.

Who researches TRH?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching respiratory health

    Studied for effects on lung function, bronchial health, or respiratory tissue.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Limited evidence: small pediatric epilepsy studies exist; they do not establish safety or efficacy for general pediatric use.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • Transient TSH and thyroid hormone elevation

    Moderate

    Protirelin (Thyrel TRH) product labeling; standard TRH stimulation-test pharmacology

  • Nausea, urge to urinate, flushing (with IV administration)

    Low

    Protirelin labeling; PubMed review of IV protirelin adverse effects (side effects described as usually mild and transient)

  • Very short half-life (~5 minutes) limiting therapeutic utility

    Low

    PMID 11814729 (Kubek & Garg, 2002); PMID 17651414 (intranasal delivery rationale); PMID 22017410 (TRH analog patent review, 2011)

  • Blood pressure changes

    Moderate

    Protirelin labeling; PubMed adverse-effect literature on IV protirelin (pressor responses; case reports of loss of consciousness/cardiac events)

Interaction summary(8)

Rated by direction with this peptide

  • Levothyroxine / liothyronine and other thyroid hormone replacement

    CautionModerate

    Exogenous thyroid hormone suppresses the pituitary and blunts or abolishes the TSH response to TRH, invalidating diagnostic testing and masking pharmacologic effect; conversely TRH on top of replacement can push a patient toward thyrotoxicosis.

    Protirelin (Thyrel TRH) product labeling; standard TRH-stimulation test methodology

  • Glucocorticoids (dexamethasone, prednisone, hydrocortisone)

    CautionModerate

    Pharmacologic corticosteroid doses suppress TSH secretion and markedly blunt the TRH-induced TSH rise, confounding both testing and any intended endocrine effect.

    Protirelin labeling (drugs that blunt TSH response); classic TRH-test endocrinology

  • Dopamine agonists and levodopa (dopamine, bromocriptine, cabergoline, levodopa)

    CautionModerate

    Dopaminergic tone tonically inhibits pituitary TSH and prolactin release, so these agents blunt both TRH-stimulated TSH and prolactin responses — clinically relevant in ICU patients on dopamine infusions and in Parkinson's patients.

    Protirelin labeling; pituitary dopaminergic-inhibition pharmacology

  • Dopamine antagonists / antipsychotics and metoclopramide

    CautionModerate

    Removing dopaminergic inhibition amplifies the TRH-induced prolactin surge, so co-administration can produce exaggerated hyperprolactinemia (galactorrhea, menstrual disruption) on top of drug-induced prolactin elevation.

    Protirelin labeling; TRH prolactin-stimulation pharmacology

  • Salicylates / high-dose aspirin

    CautionLow

    Salicylates displace thyroid hormone from binding proteins and blunt the TSH response to TRH, chiefly an interference with diagnostic interpretation rather than a safety hazard.

    Protirelin (Thyrel TRH) product labeling

  • Barbiturates and CNS depressants (including ethanol, general anesthetics)

    ProtectiveLow

    TRH is a classic analeptic that reverses barbiturate- and ethanol-induced narcosis and hypothermia in animals independently of the thyroid axis; the arousal effect is robust preclinically but has never been established as a clinical antidote in humans.

    PMID 11814729 (Kubek & Garg review, 2002); PMID 817374 (Nemeroff, 1975)

  • Opioids (opioid-induced respiratory depression)

    ProtectiveTheoretical

    TRH and its analogs counter opioid- and injury-associated respiratory depression and hypotension in animal models via non-opiate, non-naloxone-reversible mechanisms; no controlled human data support using it this way.

    PMID 2830771 (Faden, TRH and opiate-antagonist review, 1988)

  • Antiepileptic drugs (phenobarbital and other barbiturate anticonvulsants)

    SynergisticLow

    TRH potentiates the anticonvulsant action of phenobarbital in rodents and raises seizure threshold on its own, consistent with its role as an endogenous anticonvulsant — demonstrated preclinically and in small pediatric epilepsy series, not in controlled adult trials.

    PMID 817374 (Nemeroff, 1975); PMID 11814729 (Kubek & Garg, 2002); PMID 11701274 (West/Lennox-Gastaut, 2001)

Known risks(4)

  • Transient TSH and thyroid hormone elevation

    Mild

    TRH stimulates TSH release, which can transiently increase thyroid hormone levels. This is clinically significant in patients with thyroid disorders. Neuroprotective effects may occur at doses that also affect the thyroid axis.

  • Nausea, urge to urinate, flushing (with IV administration)

    Mild to Moderate

    Common transient side effects when TRH is administered intravenously, as observed in diagnostic protirelin testing. Effects typically resolve within minutes.

  • Very short half-life (~5 minutes) limiting therapeutic utility

    Pharmacokinetic Limitation

    Native TRH is rapidly degraded by pyroglutamyl aminopeptidase II and other enzymes. Continuous infusion or stabilized analogs are required for sustained neuroprotective effects.

  • Blood pressure changes

    Mild to Moderate

    TRH can cause transient increases in blood pressure and heart rate. Patients with hypertension or cardiovascular disease should be monitored.

Drug interactions(4)

  • Thyroid hormones (levothyroxine, liothyronine)

    TRH stimulates TSH secretion, which increases thyroid hormone production. Co-administration with exogenous thyroid hormones could produce hyperthyroid symptoms. Patients on thyroid replacement should be monitored.

  • Antithyroid medications (methimazole, propylthiouracil)

    TRH-stimulated TSH release may partially counteract antithyroid drug effects. The interaction is generally not clinically significant at neuroprotective doses but should be considered.

  • Dopamine agonists (levodopa, bromocriptine, pramipexole)

    Dopamine inhibits TSH release. TRH and dopamine agonists may have opposing effects on the pituitary, though neuroprotective mechanisms are distinct.

  • Anticonvulsant medications

    TRH has intrinsic anticonvulsant activity. Additive effects with standard antiepileptic drugs are theoretically possible, potentially allowing lower doses of conventional anticonvulsants.

Research & benefits

Evidence base

Evidence Level
Moderate Evidence (diagnostic use approved; therapeutic analogs approved in Japan)
Total Studies
12000
Human Participants
2000

TRH (as protirelin) has decades of clinical use as a diagnostic agent for pituitary function testing. Its therapeutic neuroprotective potential has been demonstrated in clinical studies for TBI, depression, and spinal cord injury, but the very short half-life (~5 minutes) has limited its clinical development as a stand-alone drug. The TRH analog taltirelin (Ceredist) was approved in Japan in 2000 for spinocerebellar degeneration, validating the therapeutic concept. Several clinical trials have explored TRH in depression with positive preliminary results.

Researched for(6)

Rated by confidence in the evidence

  • Neuroprotection against excitotoxic cell death in hippocampal neurons

    Low

    Protected hippocampal and cortical neurons from excitotoxic damage in animal and cell studies only.

    PMID 10323261 (hippocampal slices, 1999); PMID 19666192 (cortical neurons, 2009); PMID 25446989 (hippocampal TRH from glutaminyl cyclase, 2015)

  • Improved neurological outcomes in traumatic brain injury models

    Low

    Improved outcomes in animal brain-injury models. Human studies also examined prolonged disturbances of consciousness after head injury; these do not establish broad neuroprotective efficacy.

    PMID 3146405 (Vink, TBI rats, 1988); PMID 8145261 (McIntosh, YM-14673, 1993); PMID 1800036 (cat head injury, 1991); PMID 2830771 (Faden review, 1988)

  • Protection of dopaminergic neurons in Parkinson's disease models (via taltirelin analog)

    Speculative

    Preliminary rodent studies suggest a TRH analog protects dopamine neurons, no human Parkinson's trials exist.

    PMID 30618632 (MPTP/rotenone protection, 2018); PMID 30555300 (hemi-PD rats, 2018); PMID 39736794 (TH expression via TRHR/RARalpha, 2024)

  • Endogenous anticonvulsant activity — reduces seizure severity in epilepsy models

    Medium

    Reduces seizures in animal models, with supporting small open-label pediatric human studies but no modern trials.

    PMID 11814729 (Kubek & Garg review, 2002); PMID 8971761 (TRH mRNA in TLE model, 1997); PMID 817374 (phenobarbital potentiation, 1975); PMID 11701274 (West/Lennox-Gastaut, 2001); PMID 17651414, 19766611 (intranasal TRH)

  • Analeptic/arousal-promoting effects — reverses sedation, hypothermia, hypotension

    Medium

    Reverses sedation and hypothermia in animal studies, with arousal also seen in humans given IV TRH.

    PMID 11814729 (review of non-endocrine CNS actions); PMID 2830771 (Faden, CNS injury review); IV protirelin cardiovascular/arousal effects documented in human case and pharmacology literature

  • Antidepressant-like effects independent of thyroid axis activation

    Medium

    Human placebo-controlled trials from the 1970s show mixed, transient mood effects independent of thyroid changes.

    PMID 810198 (IV TRH double-blind, 1975); PMID 4133645 (oral, double-blind crossover, 1974); PMID 4217458 (Benkert crossover, 1974); PMID 823828 (differential antidepressant vs endocrine effects, 1976); PMID 821075 (negative oral trial, 1976)

Benefits(6)

  • Neuroprotection against excitotoxic cell death in hippocampal neurons

    Pizzi et al., Eur J Pharmacol 1999 (hippocampal slice model, glutamate/NMDA)

  • Improved neurological outcomes in traumatic brain injury models

    Faden AI, CNS Drug Reviews 2002; multiple TBI studies

  • Protection of dopaminergic neurons in Parkinson's disease models (via taltirelin analog)

    Zheng et al., Front Cell Neurosci 2018 (MPTP and rotenone models)

  • Endogenous anticonvulsant activity — reduces seizure severity in epilepsy models

    Kubek et al., Ann Neurol 1993; Alvarez-Salas et al., Int J Mol Sci 2023 (review)

  • Analeptic/arousal-promoting effects — reverses sedation, hypothermia, hypotension

    Multiple pharmacological studies since 1970s; reviewed in Alvarez-Salas et al., 2023

  • Antidepressant-like effects independent of thyroid axis activation

    Prange et al., Lancet 1972; Marangell et al., Neuropsychopharmacology 1997

Key studies(3)

  1. Alvarez-Salas E, Garcia-Luna C, de Gortari P

    International Journal of Molecular Sciences

    2023

    Comprehensive review of TRH's neuroprotective, anti-inflammatory, and neuromodulatory effects beyond thyroid function. Summarizes evidence in TBI, depression, epilepsy, neurodegeneration, and metabolic disorders. Highlights the development of stable TRH analogs as therapeutic strategy.

  2. Neuroprotective effect of TRH against excitatory amino acid-induced cell death in hippocampal slices

    Preclinical (hippocampal slices)In vitro hippocampal preparationsAcute exposure

    Pizzi M, Boroni F, Benarese M, et al.

    European Journal of Pharmacology

    1999

    TRH concentration-dependently reduced NMDA-induced toxicity in acutely dissected rat hippocampal slices. Protection was sensitive to protein kinase C inhibition and was also observed when TRH was applied during NMDA exposure.

  3. TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone

    Preclinical (cell + animal model)SH-SY5Y cells + MPTP and rotenone mouse modelsIn vitro experiments; 14-day MPTP intervention and 56-day rotenone intervention in mice.

    Zheng C, Chen G, Tan Y, et al.

    Frontiers in Cellular Neuroscience

    2018

    Taltirelin (TRH analog, 1 mg/kg) reduced ROS generation, rescued dopaminergic neuron viability, decreased phosphorylated tau and alpha-synuclein cleavage products, lowered MAO-B activity, and improved motor function in PD mouse models.

Regulation & availability

Why researchers look at it

TRH is far more than a thyroid trigger — it is an endogenous neuroprotective molecule with proven effects against excitotoxicity, seizures, and neurodegeneration. The approval of its analog taltirelin in Japan for cerebellar disease confirms that targeting the TRH system has real therapeutic value for brain disorders.

FDA status
Protirelin was previously FDA-approved as a diagnostic agent for thyroid function testing but has been discontinued in the US market. TRH is not currently FDA-approved for any therapeutic indication in the United States. Taltirelin (TRH analog) is approved in Japan but not in the US or Europe. TRH and its analogs remain under investigation for neuroprotective applications.
WADA status
Not listed on the 2026 WADA Prohibited List as a specific substance. However, TRH could theoretically stimulate the GH axis indirectly and its endocrine effects may draw scrutiny. Athletes should consult their anti-doping authority.
Prescribability
Limited — Protirelin (synthetic TRH) approved for diagnostic use in some countries; Taltirelin approved in Japan
Availability
Protirelin (synthetic TRH) is available as a pharmaceutical product for diagnostic use in some countries, though it has been discontinued in several markets including the US (Thypinone was withdrawn). Taltirelin (Ceredist) is approved and available in Japan for spinocerebellar degeneration. Protirelin is in FDA's 503B bulk drug substances Category 3.

International status

  • EU

    Available for diagnostic use

  • US

    Historically approved as protirelin for diagnostic testing; the listed US products are discontinued.

  • Japan

    Analog taltirelin approved for spinocerebellar degeneration

  • Worldwide

    Primarily diagnostic and experimental use

Regulatory timeline(8)

  1. 1969
    TRH structure determined independently by Schally and Guillemin
  2. 1977
    Nobel Prize in Physiology or Medicine awarded for TRH discovery
  3. 1976-11-05
    Protirelin (Thypinone; NDA 017638) approved by FDA for diagnostic testing.
  4. 1990s
    Extensive research on TRH neuroprotection in TBI, epilepsy, depression
  5. 2000
    Taltirelin (Ceredist) approved in Japan for spinocerebellar degeneration
  6. 2002
    Protirelin discontinued in the US market
  7. 2018
    Taltirelin shown to protect dopaminergic neurons in PD models
  8. 2023
    Major review renews interest in TRH as a therapeutic neuroprotective agent

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

Does TRH only affect the thyroid?

No. While TRH was discovered as the trigger for TSH release, it has extensive neuromodulatory effects that are completely independent of the thyroid axis. TRH acts as a neurotransmitter throughout the brain and spinal cord, with protective effects against excitotoxicity, anti-seizure properties, arousal-promoting effects, and antidepressant activity. Many of these effects occur at doses that do not significantly alter thyroid hormone levels.

Why was the TRH analog taltirelin approved in Japan?

Taltirelin (Ceredist) was approved in Japan in 2000 for the treatment of spinocerebellar degeneration, a group of neurodegenerative diseases affecting balance and coordination. Taltirelin has a much longer half-life than native TRH and demonstrated modest but significant improvements in ataxia symptoms in clinical trials.

What is the main limitation of using TRH therapeutically?

Native TRH has an extremely short plasma half-life of approximately 5 minutes, making sustained therapeutic effects difficult to achieve. This is why research has focused on developing stabilized analogs like taltirelin, which resist enzymatic degradation and maintain activity for hours rather than minutes.

Could TRH help with traumatic brain injury?

Preclinical evidence strongly supports TRH's neuroprotective effects in TBI models, where it reduces edema, improves blood flow, and enhances neurological recovery. A small number of clinical studies have shown improvements in consciousness and outcomes in TBI patients, but large-scale trials have not been completed, partly due to TRH's short half-life.